Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Adult
Aged
Aged, 80 and over
Autoantibodies
/ blood
Biomarkers, Tumor
/ blood
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Case-Control Studies
Female
Follow-Up Studies
Hepatitis
/ blood
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Lung Neoplasms
/ drug therapy
Male
Melanoma
/ drug therapy
Middle Aged
Prognosis
Prospective Studies
Survival Rate
Switzerland
/ epidemiology
Autoantibodies
Checkpoint inhibitors
Drug-induced liver injury
Drug-related side effects and adverse reactions
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
26
07
2021
accepted:
25
11
2021
pubmed:
8
12
2021
medline:
8
3
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are barely known. We investigated the association of preexisting autoantibodies in the development of ICI-induced hepatitis in a prospective cohort of cancer patients. Data from a prospective biomarker cohort comprising melanoma and non-small cell lung cancer (NSCLC) patients were used to analyze the incidence of ICI-induced hepatitis, putatively associated factors, and outcome. 40 patients with melanoma and 91 patients with NSCLC received ICI between July 2016 and May 2019. 11 patients developed ICI-induced hepatitis (8.4%). Prior to treatment, 45.5% of patients in the hepatitis cohort and 43.8% of the control cohort showed elevated titers of autoantibodies commonly associated with autoimmune liver diseases (p = 0.82). We found two nominally significant associations between the occurrence of ICI-induced hepatitis and HLA alleles associated with autoimmune liver diseases among NSCLC patients. Of note, significantly more patients with ICI-induced hepatitis developed additional irAEs in other organs (p = 0.0001). Neither overall nor progression-free survival was affected in the hepatitis group. We found nominally significant associations of ICI-induced hepatitis with two HLA alleles. ICI-induced hepatitis showed no correlation with liver-specific autoantibodies, but frequently co-occurred with irAEs affecting other organs. Unlike other irAEs, ICI-induced hepatitis is not associated with a better prognosis.
Identifiants
pubmed: 34874490
doi: 10.1007/s00432-021-03870-6
pii: 10.1007/s00432-021-03870-6
pmc: PMC8881258
doi:
Substances chimiques
Autoantibodies
0
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
647-656Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : PP00P3_157448
Organisme : Lungenliga Schweiz
ID : KLS-4409-02-2018
Informations de copyright
© 2021. The Author(s).
Références
Mod Pathol. 2018 Jun;31(6):965-973
pubmed: 29403081
J Proteome Res. 2015 Jan 2;14(1):578-86
pubmed: 25365139
Semin Liver Dis. 2018 Nov;38(4):366-378
pubmed: 30357774
Aliment Pharmacol Ther. 2019 Oct;50(7):800-808
pubmed: 31309615
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
Cancer Biol Med. 2012 Mar;9(1):57-62
pubmed: 23691457
J Clin Epidemiol. 1993 Nov;46(11):1331-6
pubmed: 8229111
Cancer Immunol Res. 2018 Sep;6(9):1039-1045
pubmed: 30002157
Clin Exp Immunol. 2018 Aug;193(2):178-182
pubmed: 29645079
Hepatol Int. 2021 Apr;15(2):510-519
pubmed: 33634373
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Immunol Immunother. 2019 Jun;68(6):917-926
pubmed: 30877325
J Immunother Cancer. 2016 Oct 18;4:60
pubmed: 27777770
Front Immunol. 2015 Aug 20;6:412
pubmed: 26347739
J Clin Pathol. 2018 Aug;71(8):665-671
pubmed: 29703758
Cancer. 1979 May;43(5):1772-6
pubmed: 36219
Drug Saf. 2009;32(1):55-68
pubmed: 19132805
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251
pubmed: 31611368
J Hepatol. 2019 Jun;70(6):1222-1261
pubmed: 30926241
Br J Cancer. 2018 Sep;119(6):661-662
pubmed: 30131552
Cancer Treat Rev. 2018 Mar;64:11-20
pubmed: 29407369
Surg Clin North Am. 2019 Apr;99(2):185-201
pubmed: 30846029
Hepatol Int. 2019 May;13(3):248-252
pubmed: 30607787
Liver Int. 2018 Jun;38(6):976-987
pubmed: 29603856
J Am Acad Dermatol. 2020 Apr;82(4):854-861
pubmed: 31449902
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Am J Surg Pathol. 2015 Aug;39(8):1075-84
pubmed: 26034866
J Dig Dis. 2019 Jul;20(7):331-337
pubmed: 31099976
Front Pharmacol. 2017 Oct 18;8:730
pubmed: 29093678
Cancer Immunol Immunother. 2021 Apr;70(4):1089-1099
pubmed: 33113003
J Immunother Cancer. 2019 Dec 17;7(1):353
pubmed: 31847881
J Hepatol. 2018 Jun;68(6):1181-1190
pubmed: 29427729
Oncoimmunology. 2016 Sep 19;5(11):e1231292
pubmed: 27999741
Clin Ther. 2019 Jan;41(1):59-67
pubmed: 30528047
Clin Exp Gastroenterol. 2017 Jan 19;10:9-18
pubmed: 28176894
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
J Autoimmun. 2004 Nov;23(3):257-66
pubmed: 15501396
Arthritis Rheumatol. 2016 Oct;68(10):2492-502
pubmed: 27059145